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Simple Summary: In this study, we investigated the impact of immune-related adverse events (irAEs)
on the survival of advanced melanoma patients treated with immune-checkpoint inhibitors, as well
as the effect of corticosteroids and other immune-modulators on clinical outcome. We summarized
the kinetics, onset, and outcome of immune-related adverse events (irAEs) in both adjuvant and
non-adjuvant settings and we correlated their onset with disease outcome.
Abstract: Immune checkpoint inhibitors (ICIs) can induce immune-related adverse events (irAEs),
which may result in treatment discontinuation. We sought to describe the onset, frequency, and
kinetics of irAEs in melanoma patients in a real-life setting and to further investigate the prognostic
role of irAEs in treatment outcomes. In this retrospective single-center cohort study, we included
249 melanoma patients. Onset, grade, and resolution of irAEs and their treatment were analyzed.
A total of 191 (74.6%) patients in the non-adjuvant and 65 (25.3%) in the adjuvant treatment setting
were identified. In the non-adjuvant setting, 29 patients (59.2%) with anti-CTLA4, 43 (58.1%) with
anti-PD1, and 54 (79.4%) with anti-PD1/anti-CTLA4 experienced some grade of irAE and these had
an improved outcome. In the adjuvant setting, the frequency of irAEs was 84.6% in anti-CTLA4 and
63.5% in anti-PD1, but no correlation with disease relapse was observed. Patients with underlying
autoimmune conditions have a risk of disease exacerbation. Immunomodulatory agents had no
impact on treatment efficacy. IrAEs are correlated with increased treatment efficacy in the non-
adjuvant setting. Application of steroids and immunomodulatory agents, such as anti-TNF-alpha
or anti-IL6, did not affect ICI efficacy. These data support irAEs as possible prognostic markers for
ICI treatment.
Keywords: immune-related adverse events; melanoma; immunotherapy; infliximab; tocilizumab
1. Introduction
Immune checkpoint inhibitors (ICIs) such as anti-PD1 (programmed cell death 1) and
anti-CTLA4 (cytotoxic T lymphocyte antigen 4) antibodies have revolutionized the therapeutic
landscape of metastatic melanoma and are approved as first-line therapies in the advanced
as well as the adjuvant setting [1–4]. However, the resulting disinhibition of T-cell responses
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can lead to a spectrum of immune-related adverse events (irAEs) that may potentially
involve any organ, but most commonly affect the skin, gastrointestinal tract, endocrine
glands, liver, lung, and musculoskeletal system [5]. Immune-related AEs are usually
manageable, yet in certain cases they can lead to ICI discontinuation or rarely, be fatal [6,7].
In patients treated with combined anti-CTLA4/anti-PD1 (ipilimumab and nivolumab),
irAEs of any grade can be observed with a frequency of up to 90% and may lead to
treatment discontinuation in up to 50% of patients [8]. Monotherapies have a better safety
profile; interestingly, the frequency and severity of irAEs differ with a higher incidence and
grade in anti-CTLA4 than in anti-PD1 regimens [1].
In the treatment of the vast majority of irAEs, corticosteroids are the standard of care.
In cases of steroid-refractory irAEs like colitis, pneumonitis, arthritis, and hepatitis, other
immunomodulatory treatments such as blocking antibodies against tumor necrosis factor
alpha (TNF-α) or interleukin 6 (IL6) were shown to be effective [5,9–11]. It remains unclear
whether these interventions have a negative impact on the antitumor immune response. A
pooled analysis of data from the CheckMate 069 and CheckMate 067 clinical trials showed
that corticosteroids do not appear to inhibit tumor response [12]. However, high-dose
steroids for long durations during anti-PD1 therapy may be associated with poorer survival
outcomes [13].
Currently, there are conflicting reports on the prognostic role of irAEs. In some
solid tumors, mainly non-small-cell lung cancer (NSCLC), several retrospective studies
clearly correlate the occurrence of irAEs under anti-PD1 with an improved response [14,15];
whereas in melanoma, this relationship is less clear [14,16–18].
The aim of this study was to describe the frequency and kinetics of irAEs in melanoma
patients treated with ICIs both in unresectable/non-adjuvant stage III/IV and in the
adjuvant setting. Furthermore, we investigated the prognostic impact of irAEs on survival
and the effect of steroids and other immunomodulators on clinical outcome.
2. Materials and Methods
In this single-center retrospective cohort study, we searched the melanoma registry
of the Department of Dermatology, University Hospital Zurich, Switzerland, which is
comprised of 2766 patients. All adult patients diagnosed with any subtype of melanoma,
who received ICI treatment in any line in the adjuvant or unresectable/non-adjuvant setting
from February 2011 to May 2020 and with a follow-up period of at least 3 months were
included. In patients with multiple ICI treatment lines, the treatment with a confirmed
irAE was chosen; if more than one treatment line had confirmed irAEs, then we chose the
first ICI treatment; in patients without any toxicities, the first ICI treatment was defined
as baseline treatment. The demographical, clinical, and pathological features of eligible
patients, including age, sex, primary melanoma origin, stage (according to the American
Joint Committee on Cancer 8th edition), and tumor treatment were obtained from our
institutional database. Moreover, the electronic medical records of included patients
were reviewed for history of autoimmune or auto-inflammatory co-morbidities prior to
treatment with ICIs. Date of onset, grade, irAE-directed treatment such as steroids and
other immunosuppressive/-modulatory agents, and resolution of irAEs were retrieved.
Grading of irAEs was based on the Common Terminology Criteria for Adverse Events
(CTCAE), version 5.0 [19].
Overall survival (OS) was calculated from the date of therapy initiation to the last
follow-up or death. Progression-free survival (PFS) was calculated from the date of ther-
apy initiation to documented disease progression or last follow-up for non-progressed
patients. Three-monthly positron emission tomography–computed tomography (PET-CT)
or computed tomography (CT) scans according to the institution protocols were used for
the assessment of treatment responses evaluated according to the RECIST criteria [20].
A total of 256 patients were subjected to analysis. Categorical variables were summa-
rized as frequencies. To assess differences in categorical variables, the Fisher’s exact test
was used. Continuous variables were summarized as median and range. For continuous
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variables, the Wilcoxon rank test was used. Survival differences were assessed with the
log-rank test. A p-value of < 0.05 was considered as statistically significant. Time-to-event
outcomes (duration of corticosteroids and immunosuppressive agents, time to resolution,
OS, PFS) were visualized by Kaplan–Meier (KM) curves. All statistical analyses were
performed by using R version 4.0.1.
3. Results
3.1. Demographics
A total of 256 patients, 191 (74.6%) in advanced/non-adjuvant and 65 (25.3%) in
adjuvant setting, with median age of 63 years (range 25–92) were identified (Table 1).


























II 4 (1.6%) - - - 2 (9.5%) 2 (4.5%)
III 65 (25%) 4 (6.2%) 10 (7.9%) 16 (76%) 35 (80%)




Cutaneous 201 (79%) 49 (75%) 97 (77%) 18 (86%) 37 (84%)
Acral 3 (1.2%) 2 (3.1%) - - 1 (2.3%)
Mucosal 14 (5.5%) 4 (6.2%) 7 (5.6%) 1 (4.8%) 2 (4.5%)
Unknown primary 24 (9.4%) 7 (11%) 11 (8.7%) 2 (9.5%) 4 (9.1%)





Chronic thyroiditis 5 (2.0%) 2 (3.1%) 2 (1.6%) 1 (4.8%) -
Diabetes type 1 3 (1.2%) 1 (1.5%) 2 (1.6%) - -
Inflammatory
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2 (0.8%) - 1 (0.8%) - 1 (2.3%)
Rheumatoid
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Multiple Sclerosis 1 (0.4%) - 1 (0.8%) - -
Bechterew’s
disease
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Toxicities, n = 44
p-Value 1
Anti-PD1 126 (49%) 31 (48%) 43 (34%) 19 (90%) 33 (75%)






Toxicity 35 (13.7%) - 25 (20%) - 10 (23%)
Disease progres-
sion/recurrence
112 (43.8%) 51 (79%) 46 (71%) 3 (14%) 12 (27%)
Treatment
completed
40 (15.6%) 1 (1.5%) 4 (3.2%) 16 (76%) 19 (43.1%)
CR 34 (13.3%) 7 (11%) 27 (21%) - -
Patient’s/Investigator’s
choice





CR 95 (40%) 8 (12%) 44 (37%) - -
PR 36 (15%) 12 (19%) 24 (20%) - -
SD 12 (5.0%) 2 (3.1%) 10 (8.4%) - -
PD 95 (40%) 42 (66%) 41 (34%) - -
1 Wilcoxon rank sum test; Fisher’s exact test; Pearson’s Chi-squared test; Abbreviations: CR; complete response, PR; partial response, SD;
stable disease, PD; progressive disease.
Of these, 170 patients (66.4%) experienced some grade (1–4, CTCAEv5) of toxicity.
The majority of the primary tumors in the overall study cohort were cutaneous (n = 201,
79%) and unknown primary (n = 24, 9.4%), and most of the patients had stage IV disease
(n = 187, 73%). The vast majority of the patients (n = 186, 73%) were treatment naïve,
whereas 27 patients (11%) had previously immunotherapy and 24 patients (9.4%) targeted
therapy. Systemic treatments included anti-PD1/anti-CTLA4 in 68 (27%) patients, single-
agent anti-PD1 in 126 (49%) patients and anti-CTLA4 in 62 (24%) patients. Median follow
up (FU) was 27 months (range 3–108) and at the end of the observation period, 92 (36%)
patients died due to melanoma, one (0.4%) patient died from adverse events and seven
(3%) patients died of other causes, while the rest of 156 (61%) patients were still alive.
3.2. Adverse Events
In the overall study population, treatment-related toxicities were reported in 11 (84.6%)
patients with anti-CTLA4 and in 33 patients (63.5%) patients with anti-PD1 in the adjuvant
setting. A total of 29 patients (59.2%) with anti-CTLA4, 43 (58.1%) patients with anti-
PD1 and 54 (79.4%) patients with anti-PD1/anti-CTLA4 in the non-adjuvant setting had
treatment-related toxicities (Figure 1A). Median time to onset of irAEs was 52 days (range
0–1328). Overall, the most common treatment-related toxicities included thyroiditis (29.4%),
colitis (27.6%), rash (24.7%), hepatitis (18.2%), arthritis (13.5%), hypophysitis (12.9%), pneu-
monitis (8.8%), vitiligo-like depigmentation (8.8%) and pancreatitis (7.6%). Other adverse
events of special interest included myocarditis (3.5%), cytokine release syndrome (CRS,
1.8%), type 1 diabetes (1.2%), uveitis (1.2%), encephalitis (0.6%), meningitis (0.6%), myositis
(0.6%) and nephritis (0.6%). In the non-adjuvant setting, combined immunotherapy was
complicated with severe (grade ≥ 3) toxicities in 58.8% of the cases, compared to 22.4% and
13.3% in anti-CTLA4 and anti-PD1 agents, respectively. In the adjuvant setting, grade 3
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and higher toxicities were reported in 38.4% and 13.5% of patients treated with anti-CTLA4
and anti-PD1, respectively (Figure 1B).
Figure 1. Frequency and time of appearance of irAEs in the adjuvant and non-adjuvant setting. (A) Barplot representing
the frequencies of any irAE by treatment faceted by the adjuvant and non-adjuvant setting. (B) Barplot representing the
frequencies of grade 3 and higher irAE by treatment faceted by the adjuvant and non-adjuvant setting. (C) Boxplots
representing the appearance of the first irAE by treatment in the adjuvant and non-adjuvant setting.
Late-onset toxicities, i.e., toxicities that were observed after treatment discontinuation,
were reported in nine patients, with median time to onset 132 days (range 100–334) after
treatment discontinuation and included most frequently endocrinological toxicities (n = 4,
including hypophysitis, thyroiditis and type 1 diabetes), skin toxicities (n = 3), pneumonitis
(n = 1) and inflammatory/CRS symptoms (n = 1). When stratified according to the treat-
ment regimen, anti-PD1 treatment was complicated more frequently with immune-related
arthritis, pneumonitis, myocarditis, thyroiditis and hematologic toxicities, whereas anti-
CTLA4-driven toxicities included colitis, hypophysitis and skin rash; types of toxicities
and kinetics according to treatment are summarized in Figure 2.
3.3. Adverse Events in Non-Adjuvant/Unresectable Setting
In the non-adjuvant/unresectable setting (AJCCv8 Stage III-IV), treatment-related
toxicities were reported in 126 patients (65.6%), of which 45% experienced ≥2 toxicities
(range 2–7) (Table 1). A total of 74 (39%), 68 (36%), and 49 (26%) patients were treated
with anti-PD1, anti-CTLA4/anti-PD1 and anti-CTLA4 respectively. Treatment-related
toxicities led to treatment discontinuation in 25 patients (20%), mostly in the combined
immunotherapy group. Median time to toxicity onset was 43.5 days (range 0–1328);
31.5 days for anti-PD1/anti-CTLA4, 44 days for anti-CTLA4 and 97 days for anti-PD1
(Figure 1C). The most frequent toxicities for combined immunotherapy included immune-
related thyroiditis (30.9%), hepatitis (29.4%) and colitis (26.5%). In the monotherapy
regimens, anti-PD1 treatment was mostly associated with skin (vitiligo-like depigmentation
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12.2%, rash 9.5%) and endocrinological (thyroiditis 19%, hypophysitis 9.5%) toxicities,
whereas colitis (34.7%) and skin rash (22.4%) were commonly observed in single-agent
anti-CTLA4 (Figure 3A).
≥
Figure 2. Density plots representing the time of appearance of arthritis, colitis, hepatitis, hypophysitis, myocarditis,
pneumonitis, rash and thyroiditis in adjuvant and non-adjuvant patients treated with anti-CTLA4, anti-PD1, and anti-
CTLA4 with anti-PD1.
Treatment discontinuation was most commonly related to combined immunotherapy,
with similar patterns as in the general study population. Of note, immune-related arthritis
led to treatment discontinuation in 8.8% of patients with combined immunotherapy, as
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well as 9.5% in single-agent anti-PD1. Similar to combination treatment, colitis was the
most frequent event that led to treatment discontinuation in anti-CTLA4 alone (18.4% and
14.7%, respectively).
3.4. Adverse Events in Adjuvant Setting
Out of the 65 patients that were treated in the adjuvant setting (AJCCv8, Stage II–IV),
44 (67.7%) patients presented with treatment-related adverse events, prompting treatment
discontinuation in 10 (23%) patients (Table 1). The selected treatment regimen was anti-
PD1 alone in 33 (75%) patients, whereas 11 (25%) patients were treated with adjuvant
anti-CTLA4, in a reduced adjuvant dose (3mg/kg Q3W). Sixteen (36.4%) patients had
multiple toxicities (range 2–5). Median time to toxicity onset was 89.5 days (range 14–546);
115 days for anti-PD1 and 55 days for anti-CTLA4 (Figure 1C). In the single-agent anti-PD1,
the toxicity pattern was similar to the non-adjuvant setting, with increasing frequency of
hepatitis (9.6%), arthritis (9.6%) and colitis (7.7%) (Figure 3B).
α
α α
Figure 3. Types/grades of irAEs and their treatments in the adjuvant and non-adjuvant setting. (A) Stacked barplots
representing the frequency of each time of irAE for anti-CTLA4, anti-PD1, and anti-CTLA4 with anti-PD1 in the non-
adjuvant setting. (B) Stacked barplots representing the frequency of each time of irAE for anti-CTLA4 and anti-PD1 in the
adjuvant setting. (C) Waffle plot showing the 292 irAEs untreated, treated with steroids, treated with anti-TNFα or anti-IL6,
and treated with steroids and anti-TNFα or anti-IL6. (D) Waffle plot showing the different irAEs treated with anti-TNFα or
anti-IL6 with and without steroids for anti-CTLA4, anti-PD1, and anti-CTLA4 with anti-PD1.
Nevertheless, and compared to the non-adjuvant group, toxicities with long-term
effects, or potentially fatal effects were more commonly observed and included endocrino-
logical toxicities (thyroiditis 15.4%, hypophysitis 11.5%), myocarditis (5.7%), meningitis
(1.9%) and encephalitis (1.9%). Immune-related colitis (5.8%), encephalitis (1.9%), meningi-
tis (1.9%), myocarditis (1.9%) and pneumonitis (1.9%) were the grade 3–4 toxicities that led
to treatment discontinuation in this group.
Similar to the non-adjuvant group, in the single-agent anti-CTLA4, colitis (30.8%) and
hypophysitis (30.8%) were frequent treatment-related toxicities that were associated with
severe, grade 3–4 adverse events in 23.1% and 15.4% of the cases, respectively.
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3.5. Immunomodulatory Agents
Out of the 292 irAEs from 170 patients, 74 events were treated with steroids alone, 28
with steroids and an immunomodulatory treatment, including either anti-TNFα (n = 25)
or anti-IL6 (n = 2) or both (n = 1). Patients received for six events anti-TNFα alone, and
184 received neither steroids nor an immunomodulatory treatment (Figure 3C). Within
the 34 cases that received an immunomodulatory agent, the vast majority (23/34) of
the toxicities were associated with anti-CTLA4/anti-PD1 and included colitis grade ≥2
(n = 13), hepatitis grade ≥3 (n = 5), arthritis grade ≥2 (n = 3), gastritis grade 3 (n = 1) and
pneumonitis grade 2 (n = 1). Other toxicities included arthritis grade 3 (n = 2) and colitis
grade 2 (n = 1), associated with single-agent anti-PD1 and colitis grade ≥2 (n = 8), associated
with anti-CTLA4 (Figure 3D). Anti-TNF-α was preferred as the immunomodulatory agent
in most colitis cases (21/22) and treatment benefit was observed in 20/21 cases; one patient
with grade 3 colitis was treated with first-line anti-TNF-α as a steroid-sparing option with
toxicity resolution. Of note, no benefit was observed in two cases of grade 3 hepatitis
and grade 3 colitis treated with anti-TNF-α, thus requiring further immunosuppression.
Anti-IL6 was administered in one case of pneumonitis grade 2 and colitis grade 3, with
toxicity resolution. A patient with colitis grade 3, who did not respond to either steroids or
anti-TNF-α, was treated with anti-IL6, with event resolution.
3.6. Patients with Underlying Autoimmune/Auto-Inflammatory Comorbidities
Twenty (7.8%) patients with underlying autoimmune or auto-inflammatory conditions
at baseline, including inflammatory bowel disease (IBD, n = 3), type 1 diabetes (n = 3),
Bechterew’s disease (n = 1), multiple sclerosis (MS, n = 1), rheumatoid arthritis (RA, n = 6),
chronic thyroiditis (n = 4) and sarcoidosis (n = 2) were identified (Table 1). At the time
of immunotherapy initiation, seven (35%) patients had an inactive underlying disease,
and five (25%) required symptomatic treatment or substitution only. Low-dose steroids
or systemic immunosuppressive treatment was present in six (30%) cases. One patient
with MS was on fingolimod treatment, which was discontinued prior to immunotherapy
(anti-PD1/anti-CTLA4), without MS exacerbation during treatment. Notably, prophylactic
treatment with anti-TNF-α was administered in a patient with inactive IBD, subsequently
treated with anti-PD1, without an IBD flare.
The majority of the patients received anti-PD1 alone (n = 11); nevertheless, six pa-
tients were treated with anti-PD1/anti-CTLA4 and three with anti-CTLA4. Five (25%)
patients tolerated the systemic treatment well, with neither treatment-related toxicities nor
disease flare, whereas fifteen (75%) patients, four from the adjuvant and eleven from the
advanced/unresectable setting, developed treatment-related toxicities and seven (35%)
patients had exacerbation of their underlying disease. Disease flare (n = 4) of inactive con-
ditions or worsening (n = 3) was noted in rheumatoid arthritis (n = 2), chronic thyroiditis
(n = 3), IBD (n = 1) and type 1 diabetes (n = 1).
3.7. Efficacy
Patients that presented with irAEs in the adjuvant setting showed no superior progno-
sis with regard to relapse-free survival (RFS) compared to the patients without irAEs, in the
different treatment regimens (p = 0.43 for anti-CTLA4 and p = 0.65 for anti-PD1, Figure 4A).
Overall survival (OS) was similar between the two groups (Figure 4B), but mOS was not
reached. Univariate Cox regression analysis for the clinical features (age, sex and presence
of irAEs) showed no significant results for RFS and OS (Figure S1).
In the non-adjuvant setting, patients with irAEs presented with more favorable PFS
compared to non-irAEs in all treatment regimens (p = 0.0036 for anti-CTLA4, p = 0.0022 for
anti-PD1 and p < 0.0001 for anti-CTLA4/anti-PD1, (Figure 4C), which was also translated
to survival benefit on OS rates except for anti-PD1 (p = 0.22, Figure 4D). Univariate Cox
regression analysis for the clinical features (age, sex, elevated LDH at treatment start and
presence of irAEs and brain metastases) showed that presence of irAEs was associated
with prolonged PFS in anti-CTLA4 (HR 0.34, p = 0.007), anti-PD1 (HR 0.32, p = 0.002) and
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anti-PD1/anti-CTLA4 (HR 0.08, p < 0.001) (Figure S2). Male sex negatively influenced
PFS in anti-CTLA4 treatment (HR 2.84, p = 0.024). Elevated LDH at treatment start was
associated with poor OS in anti-CTLA4 (HR 8.04, p < 0.001), anti-PD1 (HR 2.67, p = 0.034)
and anti-PD1/anti-CTLA4 (HR 0.16, p < 0.001). The presence of irAEs was significant
for prolonged OS in anti-CTLA4 (HR 0.34, p = 0.026) and anti-PD1/anti-CTLA4 (HR 0.16,
p < 0.001).
Patients that experienced an irAE were assessed for whether no treatment or treatment
with steroids with or without an immunomodulatory agent affected PFS and OS. Of note,
steroids and other anti-inflammatory drugs had no significant impact on progression-
free survival or overall survival in the adjuvant and non-adjuvant setting (PFS and OS,
Figure 5A–D).
Figure 4. Kaplan–Meier plots for the adjuvant and non-adjuvant setting stratified by the appearance of irAE. (A) Recurrence-
free survival for anti-CTLA4 and anti-PD1 in the adjuvant setting. (B) Overall survival for anti-CTLA4 and anti-PD1 in the
adjuvant setting. (C) Progression-free survival for anti-CTLA4, anti-PD1, and anti-CTLA4 with anti-PD1 in the non-adjuvant
setting. (D) Overall survival for anti-CTLA4, anti-PD1, and anti-CTLA4 with anti-PD1 in the non-adjuvant setting.
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Figure 5. Kaplan–Meier plots for the adjuvant and non-adjuvant settings stratified by treatment for the irAE. (A) Recurrence-
free survival in the adjuvant setting for anti-CTLA4 and anti-PD1. (B) Overall survival in the adjuvant setting for anti-CTLA4
and anti-PD1. (C) Progression-free survival in the non-adjuvant setting for anti-CTLA4, anti-PD1, and anti-CTLA4 with
anti-PD1. (D) Overall survival in the non-adjuvant setting for anti-CTLA4, anti-PD1, and anti-CTLA4 with anti-PD1.
4. Discussion
Although ICIs are currently in widespread use in oncology and their efficacy in
melanoma patients is unquestionable, there is contradictory evidence on the correlation
of irAEs with clinical outcome. In this retrospective study, patients with irAEs showed
improved PFS in all unresectable/non-adjuvant treatment regimens, compared to patients
without irAEs. In combined immunotherapy with anti-PD1/anti-CTLA4, the presence
of irAEs was associated with an OS benefit as well. As such, irAEs may represent an
indicator of treatment efficacy in these patients. Of note, in the adjuvant setting, no
correlation of irAEs and relapse-free or OS was observed. Organ-specific irAEs differed
between the two agents; anti-PD1 treatment was complicated more frequently with arthritis,
pneumonitis, myocarditis, thyroiditis and hematologic toxicities, whereas anti-CTLA4-
driven toxicities included colitis, hypophysitis and skin rash. Treatment of irAEs with
steroids and other immunomodulatory agents, such as anti-TNFα and anti-IL6, had no
impact on treatment efficacy.
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Our results are in line with several retrospective studies suggesting significant benefit
towards tumor control and survival in immunotherapy-treated patients that experience
any kind of irAE, with the majority of reports coming from non-small-cell lung cancer
field (NSCLC) [14,15,21,22]. However, for melanoma, the association between toxicity and
efficacy is not as linear as observed in other cancer types. The majority of published studies
have indicated either a confirmed PFS or OS benefit for dermatologic toxicities (especially
for hypopigmentation) or no benefit at all; a retrospective study of melanoma patients
treated with anti-PD1 reported OS benefit in patients with irAEs but in the multivariate
analysis only ≥ grade 3 toxicities remained a significant confounder for OS [23,24]. A
pooled analysis of the Keynote 001, 002 and 006 clinical trials in advanced melanoma
patients treated with pembrolizumab demonstrated no efficacy difference in patients with
irAEs compared to no irAE at the landmark analysis of 21 weeks. Still, the analysis was
conducted only in 29.5% of the total population (463/1567 patients) including only those
that did not progress until week 21, therefore excluding both patients with innate early
resistance or those with late toxicities [18].
Notably, the frequency and type of irAE differed significantly in the adjuvant setting.
This was particularly prominent in anti-PD1 treatment and in all grades of irAEs, but
frequency of ≥ grade 3 irAEs was similar between the adjuvant and non-adjuvant setting.
This observation is pertinent for risk/benefit assessment in adjuvant treatment, as many
patients may already be cured by surgery alone. Furthermore, we observed a higher
incidence of toxicities with long-term effects, or potentially fatal toxicities in the adjuvant
setting with an increased frequency of myocarditis (6.7%), meningitis (2.2%), encephalitis
(2.2%) and endocrinological toxicities (thyroiditis 17.8% and hypophysitis 13.3%). In fact,
irAEs with long-term or potentially fatal effects were more commonly observed than in the
non-adjuvant setting and this risk should not be neglected in adjuvant treatment decision
in resected melanoma [25]. The difference in frequency of irAEs might be attributed
to the treatment exposure time and the patient’s intrinsic factors, as well as immune
status in stage III compared to advanced, unresectable melanoma [26]. In contrast to a
recent report of the EORTC-1325/Keynote-054 study in patients with resected Stage III
melanoma, where the presence of endocrine and skin toxicities in the pembrolizumab arm
was correlated with improved RFS rates, our study did not confirm this superiority in
risk of progression in the adjuvant setting [17]. However, the small number of patients in
this setting precludes any statistical conclusion. Interestingly and besides the appearance
of vitiligo-like depigmentation under interferons [27], no other reports with anti-PD1 or
anti-CTLA4 monotherapy have been published so far confirming the prognostic value of
irAEs in the adjuvant setting either prospectively or retrospectively.
In our cohort, 66.4% experienced at least one irAE; 79% with anti-PD1/anti-CTLA4,
60% with anti-PD1 and 64% with anti-CTLA4 alone, which is in the expected range, com-
pared to data from randomized clinical trials. Notably, median time to toxicity onset was
longer in the adjuvant setting versus non-adjuvant (89.5 versus 43.5 days). This is probably
treatment-regimen-associated since more than 2/3 of the patients in the non-adjuvant
setting received an anti-CTLA4-directed treatment, either alone or in combination with
anti-PD1. Besides, nivolumab was initially tested at 3 mg/kg 2-weekly in the CheckMate-
238 trial [4] and nivolumab/ipilimumab are administered at a dose of 1 and 3 mg/kg
3-weekly at the induction phase. Nivolumab, which is the treatment regimen preferred
in the adjuvant setting, is now also approved and administered as a flat dose of 480 mg
4-weekly. While it is likely that such alterations in dosing and schedule do not impact
efficacy or toxicity, the optimal treatment duration is not known and data from alternative
dosing schedules from anti-CTLA4 should be thoroughly reviewed. In the adjuvant setting,
ipilimumab is approved at a dose of 10 mg/kg, but its use is limited due to high toxicity.
As such, we applied adjuvant ipilimumab in the conventional dose of 3 mg/kg 3-weekly,
with significantly improved tolerability [28]. Although in the Checkmate-511 trial the
induction dose of anti-CTLA4 does not seem to affect efficacy [29], in the Checkmate-915
Cancers 2021, 13, 2931 12 of 15
trial, low-dose ipilimumab combined with nivolumab was not superior to nivolumab
alone [30].
Our data suggest that steroids for irAEs or other immunomodulating agents for
steroid-refractory toxicities do not have a direct impact on prognosis. Similar results
have been reported in other studies and in a pooled analysis of pembrolizumab with
patients that received steroids for irAEs experiencing similar efficacy outcomes with those
without [12,18,31]. However, the impact of duration of the immunosuppressive treatment
on disease outcome was not addressed in this study. In a secondary analysis of the
EORTC-1325/Keynote-054 study, treatment effect of adjuvant pembrolizumab after 30 days
of systemic steroid use appeared to be lower than without steroid use or by day 30 of
systemic steroid use [17]. In another recent multicenter observational study on concomitant
medications and outcomes in patients with solid tumors treated with ICIs, patients with
steroids at baseline for cancer-related indications had significantly worse PFS and OS than
those without or those with steroids for non-cancer-related indications [32]. Nevertheless,
the authors did not include patients with irAEs requiring steroids in the non-cancer-related
indications group. Taken all together, we assume that steroids given for irAEs for a short
time or those given for symptom control have different effects on survival and outcome
with the first neutralizing the detrimental effect by the positive effect of immune-mediated
toxicity itself. Approximately 20% of steroid-refractory irAEs required additional treatment,
with the majority of those having received TNF-α inhibitors. Rapid resolution was observed
in almost all cases with colitis. The relatively high rate of TNF-α or IL-6 inhibitors in our
cohort is a result of our clinical judgment that early treatment or treatment in lower irAEs
grades (e.g., grade 2) is preferable to prolonged treatment with high-dose corticosteroids.
A minority in our study cohort had underlying autoimmune toxicities, with only 35%
of those experiencing a flare of their disease and 75% of those experiencing any kind of irAE.
A previous study has reported a similar incidence of autoimmune disease exacerbation
in 52 melanoma patients treated with anti-PD1 monotherapy [33]. In the same study, no
patients with previous gastrointestinal disease flared upon exposure to ICIs: however, one
patient in our study with inactive IBD started prophylactic treatment with a TNF-α inhibitor
upon initiation of ICIs. This probably suggests that the pathogenesis of autoimmunity is
heterogeneous with many disorders not relying on PD1 or CTLA4 pathway.
Noteworthy, 5% (n = 9) of our patients experienced late-onset irAEs, defined as an
irAE that occurred after treatment discontinuation, with endocrinological toxicities, skin
toxicities and pneumonitis being the most frequent ones. These findings are comparable
with a recent multicenter retrospective analysis reporting an estimated incidence of 5.7%
of late onset irAEs and an identical pattern [34]. Although the incidence is low, late-onset
irAEs can be difficult to manage and are definitely affecting patient’s quality of life.
Our study has a number of limitations, including the retrospective, single-center de-
sign and low number of patients in some subgroups especially in the adjuvant setting, those
with prior autoimmune diseases and those receiving steroids or other immunomodulating
agents for irAEs. In addition, we must consider that since the cohort was not collected
prospectively, under-reporting of mild toxicities cannot be excluded. On the other hand, it
represents a relatively large homogenous cohort of exclusively melanoma patients treated
with ICIs beyond clinical trials.
5. Conclusions
In conclusion, the appearance of irAEs in the non-adjuvant setting is undoubtedly
associated with significant outcome benefit. We confirm previous reports on the low
number of autoimmune disease flares with ICIs and support the non-significant impact of
steroids and other immunomodulating agents, when administered early and for a short
time, for irAE management on clinical outcome. Further elucidation of the predictive and
prognostic role of irAEs in the prospective setting is warranted.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/cancers13122931/s1, Figure S1: Univariate Cox regression analysis for covariates in the
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adjuvant setting, Figure S2: Univariate Cox regression analysis for covariates in the unresectable/non-
adjuvant setting.
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